John Mendlein
Gründer bei FATE THERAPEUTICS, INC.
Vermögen: 1 Mio $ am 30.04.2024
Ursprung des Netzwerks ersten Grades von John Mendlein
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
Flagship Pioneering
 Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts.
186
| Private Company | Investment Managers | 186 |
| Public Company | Biotechnology | 42 | |
| Public Company | Pharmaceuticals: Major | 34 | |
| Public Company | Biotechnology | 20 | |
Monogram Biosciences, Inc.
 Monogram Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Monogram Biosciences, Inc. develops and commercializes diagnostic products for the treatment of human immunodeficiency virus (HIV) infection, hepatitis C virus (HCV) infection, and other viral illnesses, as well as cancer and other diseases. It offers HIV tests, including genotypic, phenotypic, tropism, and combined phenotype and genotype assays, suppression management and viral load testing, HCV assays and oncology tests. The company was founded in 1995 and is headquartered in South San Francisco, CA.
11
| Holding Company | Miscellaneous Commercial Services | 11 |
Tessera Therapeutics, Inc.
 Tessera Therapeutics, Inc. BiotechnologyHealth Technology Tessera Therapeutics, Inc. engages in science company. It offers scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. The company is headquartered in Cambridge, MA.
11
| Holding Company | Biotechnology | 11 |
Aurora Biosciences Corp.
 Aurora Biosciences Corp. BiotechnologyHealth Technology Aurora Biosciences Corp. designs and develops proprietary drug discovery systems, services and technologies to the discovery of new medicine. It develops a proprietary ultra-high throughput screening platform that uniquely integrates innovative fluorescence chemistry, molecular biology, miniaturization, automation, and informatics. The company also provides assay development and screening services. Aurora was founded in 1995 and is located in San Diego, CA.
9
| Holding Company | Biotechnology | 9 |
Affinium Pharmaceuticals Ltd.
 Affinium Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Affinium Pharmaceuticals Ltd. is a holding company, which engages in the provision of clinical development of antibacterial. It specializes in hte development of antibiotics that targets the bacterial fatty acid synthesis pathway. It focuses on small molecule antibacterials targeting FabI, an essential enzyme in the bacterial fatty acid cycle. The company was founded in 2000 and is headquartered in Austin, TX.
8
| Extinct | Pharmaceuticals: Major | 8 |
Adnexus
 Adnexus Pharmaceuticals: MajorHealth Technology Adnexus engages in the development of Adnectins biologics and medicines in the United States. The company was founded by Frank D. Lee on September 16, 2002 and is headquartered in Waltham, MA.
8
| Subsidiary | Pharmaceuticals: Major | 8 |
Ohana Biosciences, Inc.
 Ohana Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Ohana Biosciences, Inc. operates early stage biotechnology firm. The company is headquartered in Cambridge, MA.
7
| Holding Company | Miscellaneous Commercial Services | 7 |
ACLARA Biosciences, Inc.
 ACLARA Biosciences, Inc. Medical SpecialtiesHealth Technology ACLARA Biosciences, Inc. discovers, develops and markets innovative products to guide and improve treatment of serious viral, immunologic, and oncologic diseases.
2
| Extinct | Medical Specialties | 2 |
Empress Therapeutics, Inc.
 Empress Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Empress Therapeutics, Inc. is a company that was founded by Flagship Pioneering in 2020. The company is based in Cambridge, MA. Empress Therapeutics generates medicines quickly by using the chemistry inside the human body. The company uses the Empress Chemilogics™ platform to create first- or oral medicines for a broad range of diseases quickly, predictably, and cost-effectively. The platform uses novel insights that connect the lines of code in DNA with drug-like chemistry made in the human body. Jason Park is the founder of the company and has been the CEO since incorporation.
2
| Holding Company | Pharmaceuticals: Major | 2 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von John Mendlein
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| Massachusetts Institute of Technology | College/University | Corporate Officer/Principal Director/Board Member Doctorate Degree Corporate Officer/Principal Doctorate Degree Doctorate Degree Doctorate Degree Undergraduate Degree Graduate Degree Graduate Degree Undergraduate Degree | |
| AXCA HEALPAR | Biotechnology | Founder Director/Board Member Director of Finance/CFO Founder Founder Director/Board Member | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin Corporate Officer/Principal Masters Business Admin | |
Montai Health, Inc.
 Montai Health, Inc. Packaged SoftwareTechnology Services Montai Health, Inc. is a company that is using its pioneering AI-powered Conecta™ platform to develop Anthromolecule™ medicines that will treat and preempt chronic diseases to improve health outcomes for the 2 billion people worldwide living with these diseases. The company is based in Cambridge, MA. Montai Health is unlocking the potential of Anthromolecule™ chemistry with its pioneering AI-powered Conecta™ platform to develop breakthrough small-molecule medicines that will treat and preempt chronic diseases to improve health outcomes for the two billion people worldwide living with these diseases. The company was founded by Hok Hei Tam, Michael Wong, David Kolesky, Mary Margaret Hastings Georgiadis. Mary Margaret Hastings Georgiadis has been the CEO since incorporation. | Packaged Software | Founder Director/Board Member Director/Board Member Founder Chief Operating Officer | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| University of Maryland | College/University | Graduate Degree Undergraduate Degree Undergraduate Degree Graduate Degree Doctorate Degree | |
| EVELO BIOSCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member Founder Director/Board Member Founder Director/Board Member | |
Generate Biomedicines, Inc.
 Generate Biomedicines, Inc. BiotechnologyHealth Technology Generate Biomedicines, Inc. is a drug generation company that has developed a machine learning-powered multimodality generative biology platform capable of generating new drugs on demand across a wide range of biologic modalities. Generate Biomedicines is based in Somerville, MA. The platform seamlessly integrates computational and wet lab capabilities, improving the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company's platform represents a potentially fundamental shift in what's possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. The company was founded in 2018 by Poorya Hosseini, Molly Gibson, Geoffrey von Maltzahn, Avak Kahvejian, Gevorg Grigoryan. Michael T. Nally has been the CEO of the company since 2018. | Biotechnology | Founder Founder Director/Board Member Chief Executive Officer President | |
| RECEPTOS INC | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Private Equity Investor | |
| CELGENE | Biotechnology | Chief Tech/Sci/R&D Officer Chief Executive Officer Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| University of Oxford | College/University | Doctorate Degree Doctorate Degree Doctorate Degree Undergraduate Degree | |
| University of California San Diego | College/University | Graduate Degree Graduate Degree Corporate Officer/Principal Undergraduate Degree | |
Inzen Therapeutics, Inc.
 Inzen Therapeutics, Inc. BiotechnologyHealth Technology Part of Sonata Therapeutics, Inc., Inzen Therapeutics, Inc. is discovering and developing a novel class of medicines based on thanokine biology. The company is based in Cambridge, MA. Thanokine biology offers the potential for unprecedented approaches to prevent and treat cancer, fibrotic disorders, immune-inflammatory disorders, metabolic disorders, and degenerative diseases. Inzen's thanokine product platform applies advances in mass spectrometry and machine learning, novel probes, unique assays, genetic and chemical biological technologies to characterize thanokine biology at scale and create drug candidates. Inzen Therapeutics harnesses signals of the cellular microenvironment to treat serious diseases. The company was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member President | |
| KALEIDO BIOSCIENCES, INC. | Pharmaceuticals: Major | Chairman Founder Chief Administrative Officer Founder | |
KSQ Therapeutics, Inc.
 KSQ Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology KSQ Therapeutics, Inc. develops and deploys precision functional genomics to discover therapies that transform patient lives. The company was founded by Tim Wang and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Chairman Director/Board Member Founder Director/Board Member | |
| MODERNA, INC. | Biotechnology | Director/Board Member Founder Founder Director/Board Member | |
| Yale University | College/University | Doctorate Degree Undergraduate Degree Doctorate Degree Graduate Degree | |
| SYROS PHARMACEUTICALS, INC. | Biotechnology | Founder Director/Board Member Founder Director/Board Member | |
| SERES THERAPEUTICS, INC. | Biotechnology | Founder Founder Founder Chairman | |
| University of Cambridge | College/University | Doctorate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| Harvard Medical School | College/University | Corporate Officer/Principal Doctorate Degree Graduate Degree Doctorate Degree | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Private Equity Investor Corporate Officer/Principal | |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | College/University | Undergraduate Degree Doctorate Degree Undergraduate Degree | |
Cellarity Inc.
 Cellarity Inc. BiotechnologyHealth Technology Cellarity Inc. engages in the operation of platform to design medicines targeting the full cellular and molecular complexity of disease. The company was founded by Avak Kahvejian, James J. Collins, Noubar Afeyan, and Nicholas Plugis in 2017 and is headquartered in Cambridge, MA. | Biotechnology | Founder Chairman President | |
TARIS BioMedical LLC
 TARIS BioMedical LLC Pharmaceuticals: MajorHealth Technology TARIS BioMedical LLC operates as a clinical-stage pharmaceutical company. It specializes in urology, continuous local dosing, bladder diseases, oncology, voiding dysfunction. The company was founded by Robert S. Langer Jr., Christine Bunt, and Michael J. Cima in 2008 and is headquartered in Lexington, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
Cobalt Biomedicine, Inc.
 Cobalt Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Cobalt Biomedicine, Inc. engages in the development of therapeutic based drugs. The company was founded in 2017 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Executive Officer | |
| NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal General Counsel | |
| AMGEN INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Repertoire Immune Medicines, Inc.
 Repertoire Immune Medicines, Inc. Miscellaneous Commercial ServicesCommercial Services Repertoire Immune Medicines, Inc. operates as a clinical-stage biotechnology company. It focuses on the immune system to prevent, treat, and cure cancer, autoimmune disorders, and infectious diseases. The company was founded by Noubar Afeyan and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Founder Chairman Director/Board Member | |
| SANA BIOTECHNOLOGY, INC. | Biotechnology | Founder Director/Board Member Director/Board Member | |
Indigo Ag, Inc.
 Indigo Ag, Inc. BiotechnologyHealth Technology Indigo Ag, Inc. provides microbial solutions. The company was founded by Noubar Afeyan, David A. Berry, and Geoffrey von Maltzahn in 2013 and is headquartered in Charlestown, MA. | Biotechnology | Founder Founder Founder | |
| RUBIUS THERAPEUTICS | Biotechnology | Founder Director/Board Member Director of Finance/CFO | |
| University of California, Los Angeles | College/University | Doctorate Degree Undergraduate Degree Undergraduate Degree | |
| University of California, Berkeley | College/University | Graduate Degree Doctorate Degree Doctorate Degree | |
Ampersand Biomedicines
 Ampersand Biomedicines BiotechnologyHealth Technology Ampersand Biomedicines is an American company that designs programmable medicines that work precisely where needed in the body and nowhere else. The company's computationally powered platform identifies ideal addresses for drug localization and informs the design of and-body™ therapeutics that have the optimal therapeutic effect. The result is smarter biologic medicines that target the site of disease without affecting healthy tissue or cells. Ampersand is enabling potent mechanisms to treat disease by creating and programming therapeutics that are more efficacious, without compromising on safety or tolerability. The company was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering. Jason Gardner has been the CEO of the company since 2023. | Biotechnology | Founder Chief Executive Officer Founder | |
Cygnal Therapeutics, Inc.
 Cygnal Therapeutics, Inc. BiotechnologyHealth Technology Cygnal Therapeutics, Inc. develops drugs for cancer, immunological diseases and regenerative processes. The company was founded by Noubar Afeyan, Avak Kahvejian and Jordi Mata-Fink in 2017 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Founder Director/Board Member | |
| T2 BIOSYSTEMS, INC. | Medical Specialties | Director/Board Member Director/Board Member Founder | |
| New York University | College/University | Graduate Degree Undergraduate Degree Undergraduate Degree | |
| CODIAK BIOSCIENCES | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Tech/Sci/R&D Officer | |
Leerink Partners LLC
 Leerink Partners LLC Investment Banks/BrokersFinance Leerink Partners LLC is a full-service brokerage and investment banking firm headquartered in Boston, Massachusetts. The firm was founded by Jeffrey Leerink in 1995 and formerly known as SVB Securities LLC. They rebranded as Leerink Partners in 2023. The firm is a subsidiary of SVB Securities LLC. Leerink Partners provides institutional sales, equity research, institutional trading, and corporate finance and asset management services to the healthcare and technology industries. They offer superior execution capabilities in common stock, convertibles and derivatives with a singular focus on healthcare and a knowledge-led approach. | Investment Banks/Brokers | Consultant / Advisor Analyst-Equity Analyst-Equity | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Undergraduate Degree Undergraduate Degree Doctorate Degree | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
| Princeton University | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
CiBO Technologies, Inc.
 CiBO Technologies, Inc. Packaged SoftwareTechnology Services CiBO Technologies, Inc. is a science-driven software company which engage sin the modelling and simulation of agricultural ecosystems. The firm offers CIBO and CIBO Plus software products. The company was founded by Ignacio Bemposta Martinez and Bruno Basso in 2015 and is headquartered in Cambridge, MA. | Packaged Software | Director/Board Member Director/Board Member Director/Board Member |
Statistik
International
| Vereinigte Staaten | 48 |
| Vereinigtes Königreich | 3 |
| Schweiz | 2 |
Sektoral
| Health Technology | 30 |
| Consumer Services | 15 |
| Finance | 3 |
| Technology Services | 3 |
| Commercial Services | 3 |
Operativ
| Director/Board Member | 440 |
| Corporate Officer/Principal | 144 |
| Independent Dir/Board Member | 114 |
| Founder | 106 |
| Chief Executive Officer | 90 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Noubar Afeyan | 76 |
| Amir Nashat | 49 |
| Douglas Cole | 44 |
| Margo Georgiadis | 34 |
| David Berry | 31 |
| Ed Kania | 31 |
| Michael Rosenblatt | 31 |
| Theo Melas-Kyriazi | 26 |
| Stuart J. M. Collinson | 25 |
| William Rastetter | 24 |
| Timothy James Rink | 23 |
| Paul Grayson | 21 |
| Robert Epstein | 20 |
| Mary Szela | 19 |
| Luke Beshar | 19 |
- Börse
- Insiders
- John Mendlein
- Unternehmensverbindungen
